Cargando…

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

OBJECTIVE: Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burm, Rani, Maravelia, Panagiota, Ahlen, Gustaf, Ciesek, Sandra, Caro Perez, Noelia, Pasetto, Anna, Urban, Stephan, Van Houtte, Freya, Verhoye, Lieven, Wedemeyer, Heiner, Johansson, Magnus, Frelin, Lars, Sällberg, Matti, Meuleman, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176361/ https://www.ncbi.nlm.nih.gov/pubmed/35977815 http://dx.doi.org/10.1136/gutjnl-2022-327216

Ejemplares similares

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
por: Maravelia, Panagiota, et al.
Publicado: (2020)

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
por: Burm, Rani, et al.
Publicado: (2022)

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model
por: Levander, Sepideh, et al.
Publicado: (2018)

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
por: Ahlén, G, et al.
Publicado: (2009)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

Editorial: HBV—the naked truth?
por: Pasetto, Anna, et al.
Publicado: (2019)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Functional Aspects of Intrahepatic Hepatitis B Virus-specific T Cells Induced by Therapeutic DNA Vaccination
por: Brass, Anette, et al.
Publicado: (2015)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses
por: Holmström, Fredrik, et al.
Publicado: (2016)

A targeted controlled force injection of genetic material in vivo
por: Ahlén, Gustaf, et al.
Publicado: (2016)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans
por: Frelin, Lars, et al.
Publicado: (2009)

Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products
por: Silva, Daniela Nascimento, et al.
Publicado: (2022)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients
por: Lybeck, Charlotte, et al.
Publicado: (2019)

Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation
por: Sällberg, Matti, et al.
Publicado: (2020)

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
por: Ahlén, Gustaf, et al.
Publicado: (2020)

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo
por: Allweiss, Lena, et al.
Publicado: (2022)

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
por: Allweiss, Lena, et al.
Publicado: (2023)

Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
por: Weiland, Ola, et al.
Publicado: (2013)

Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
por: Pasetto, Anna, et al.
Publicado: (2012)

Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
por: Maravelia, Panagiota, et al.
Publicado: (2021)

Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects
por: Kechagias, S, et al.
Publicado: (2008)

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection
por: Deuffic-Burban, S, et al.
Publicado: (2008)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection
por: Fitzmaurice, Karen, et al.
Publicado: (2011)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2011)

Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men
por: Thomson, Emma C, et al.
Publicado: (2010)

The paradox of NKp46(+) natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment
por: Pembroke, Tom, et al.
Publicado: (2014)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas
por: Govaere, Olivier, et al.
Publicado: (2014)

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
por: Chan, Tim Hon Man, et al.
Publicado: (2014)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tkssjkt58iu2qf1aelrm84iqfl